Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2018
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2018
SUMMARY
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins.
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 26 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 6, 1, 10 and 5 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders and Ophthalmology which include indications Rheumatoid Arthritis, Alopecia, Atopic Dermatitis (Atopic Eczema), Psoriasis, Vitiligo, Crohn's Disease (Regional Enteritis), Diffuse Large B-Cell Lymphoma, Inflammation, Ulcerative Colitis, Allergic Conjunctivitis, Androgenic Alopecia, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Autoimmune Disorders, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cachexia, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Cutaneous T-Cell Lymphoma, Dermatomyositis, Dermatosis, Follicular Lymphoma, Heart Transplant Rejection, Inflammatory Bowel Disease, Juvenile Rheumatoid Arthritis, Leukemias, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Myeloproliferative Disorders, Peripheral T-Cell Lymphomas (PTCL), Pruritus, Psoriatic Arthritis, Sarcopenia, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
The latest report Tyrosine Protein Kinase JAK3 - Pipeline Review, H2 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins.
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 26 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 6, 1, 10 and 5 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders and Ophthalmology which include indications Rheumatoid Arthritis, Alopecia, Atopic Dermatitis (Atopic Eczema), Psoriasis, Vitiligo, Crohn's Disease (Regional Enteritis), Diffuse Large B-Cell Lymphoma, Inflammation, Ulcerative Colitis, Allergic Conjunctivitis, Androgenic Alopecia, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Autoimmune Disorders, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cachexia, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Cutaneous T-Cell Lymphoma, Dermatomyositis, Dermatosis, Follicular Lymphoma, Heart Transplant Rejection, Inflammatory Bowel Disease, Juvenile Rheumatoid Arthritis, Leukemias, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Myeloproliferative Disorders, Peripheral T-Cell Lymphomas (PTCL), Pruritus, Psoriatic Arthritis, Sarcopenia, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
The latest report Tyrosine Protein Kinase JAK3 - Pipeline Review, H2 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Arrien Pharmaceuticals LLC
Bristol-Myers Squibb Co
Chipscreen Biosciences Ltd
Clevexel Pharma SAS
Daewoong Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Japan Tobacco Inc
KBP BioSciences Co Ltd
LSK BioPartners Inc
Merck & Co Inc
MYOS RENS Technology Inc
Portola Pharmaceuticals Inc
Sienna Biopharmaceuticals Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles
ARN-4079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-1777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVXL-0074 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delgocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWJ-212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-7536 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSK-9985 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OST-122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OST-246 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peficitinib hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06651600 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ITK and JAK3 for Psoriasis and Inflammatory Dermatoses - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK1 and JAK3 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Cachexia, Rheumatoid Arthritis and Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNA-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tofacitinib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tofacitinib citrate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Nov 01, 2018: Portola Pharmaceuticals to present new interim phase 2 results for Cerdulatinib during an oral session at the 60th American Society of Hematology (ASH) Annual Meeting
Oct 22, 2018: Theravance Biopharma reports data from TD-1473 phase 1b four-week study in oral late-breaker presentation at UEG Week 2018
Oct 10, 2018: Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018
Oct 09, 2018: Health Canada approves new indications for Xeljanz in ulcerative colitis (UC) and psoriatic arthritis (PsA)
Sep 25, 2018: Portola Pharmaceuticals receives FDA Orphan Drug Designation for Cerdulatinib, an oral Syk/JAK inhibitor for the treatment of Peripheral T-Cell Lymphoma
Sep 17, 2018: Pfizer reports positive data from Phase lla study for alopecia areata
Sep 05, 2018: Pfizer receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 inhibitor, for the treatment of patients with Alopecia Areata
Aug 27, 2018: Sienna Biopharmaceuticals announces results from first-in-human study of SNA-125 in psoriasis and continued progression to phase
Aug 01, 2018: Pfizer’s Xeljanz secures marketing authorisation in Europe
Jul 09, 2018: FDA grants Fast Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor for the treatment of Alopecia Areata
Jun 28, 2018: XELJANZ (tofacitinib citrate) Receives Marketing Authorization in the European Union for Active Psoriatic Arthritis
Jun 28, 2018: Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata
Jun 26, 2018: Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis
Jun 04, 2018: New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor Cerdulatinib
Jun 01, 2018: Pfizer Receives Positive CHMP Opinion in European Union for XELJANZ (tofacitinib citrate) for the Treatment of Moderately to Severely Active Ulcerative Colitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Arrien Pharmaceuticals LLC
Bristol-Myers Squibb Co
Chipscreen Biosciences Ltd
Clevexel Pharma SAS
Daewoong Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Japan Tobacco Inc
KBP BioSciences Co Ltd
LSK BioPartners Inc
Merck & Co Inc
MYOS RENS Technology Inc
Portola Pharmaceuticals Inc
Sienna Biopharmaceuticals Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles
ARN-4079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-1777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVXL-0074 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delgocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWJ-212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-7536 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSK-9985 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OST-122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OST-246 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peficitinib hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06651600 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ITK and JAK3 for Psoriasis and Inflammatory Dermatoses - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK1 and JAK3 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Cachexia, Rheumatoid Arthritis and Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNA-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tofacitinib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tofacitinib citrate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Nov 01, 2018: Portola Pharmaceuticals to present new interim phase 2 results for Cerdulatinib during an oral session at the 60th American Society of Hematology (ASH) Annual Meeting
Oct 22, 2018: Theravance Biopharma reports data from TD-1473 phase 1b four-week study in oral late-breaker presentation at UEG Week 2018
Oct 10, 2018: Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018
Oct 09, 2018: Health Canada approves new indications for Xeljanz in ulcerative colitis (UC) and psoriatic arthritis (PsA)
Sep 25, 2018: Portola Pharmaceuticals receives FDA Orphan Drug Designation for Cerdulatinib, an oral Syk/JAK inhibitor for the treatment of Peripheral T-Cell Lymphoma
Sep 17, 2018: Pfizer reports positive data from Phase lla study for alopecia areata
Sep 05, 2018: Pfizer receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 inhibitor, for the treatment of patients with Alopecia Areata
Aug 27, 2018: Sienna Biopharmaceuticals announces results from first-in-human study of SNA-125 in psoriasis and continued progression to phase
Aug 01, 2018: Pfizer’s Xeljanz secures marketing authorisation in Europe
Jul 09, 2018: FDA grants Fast Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor for the treatment of Alopecia Areata
Jun 28, 2018: XELJANZ (tofacitinib citrate) Receives Marketing Authorization in the European Union for Active Psoriatic Arthritis
Jun 28, 2018: Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata
Jun 26, 2018: Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis
Jun 04, 2018: New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor Cerdulatinib
Jun 01, 2018: Pfizer Receives Positive CHMP Opinion in European Union for XELJANZ (tofacitinib citrate) for the Treatment of Moderately to Severely Active Ulcerative Colitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Aclaris Therapeutics Inc, H2 2018
Pipeline by Arrien Pharmaceuticals LLC, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Chipscreen Biosciences Ltd, H2 2018
Pipeline by Clevexel Pharma SAS, H2 2018
Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018
Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2018
Pipeline by Japan Tobacco Inc, H2 2018
Pipeline by KBP BioSciences Co Ltd, H2 2018
Pipeline by LSK BioPartners Inc, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by MYOS RENS Technology Inc, H2 2018
Pipeline by Portola Pharmaceuticals Inc, H2 2018
Pipeline by Sienna Biopharmaceuticals Inc, H2 2018
Pipeline by Simcere Pharmaceutical Group, H2 2018
Pipeline by Theravance Biopharma Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Aclaris Therapeutics Inc, H2 2018
Pipeline by Arrien Pharmaceuticals LLC, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Chipscreen Biosciences Ltd, H2 2018
Pipeline by Clevexel Pharma SAS, H2 2018
Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018
Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2018
Pipeline by Japan Tobacco Inc, H2 2018
Pipeline by KBP BioSciences Co Ltd, H2 2018
Pipeline by LSK BioPartners Inc, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by MYOS RENS Technology Inc, H2 2018
Pipeline by Portola Pharmaceuticals Inc, H2 2018
Pipeline by Sienna Biopharmaceuticals Inc, H2 2018
Pipeline by Simcere Pharmaceutical Group, H2 2018
Pipeline by Theravance Biopharma Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Aclaris Therapeutics Inc
Arrien Pharmaceuticals LLC
Bristol-Myers Squibb Co
Chipscreen Biosciences Ltd
Clevexel Pharma SAS
Daewoong Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Japan Tobacco Inc
KBP BioSciences Co Ltd
LSK BioPartners Inc
Merck & Co Inc
MYOS RENS Technology Inc
Portola Pharmaceuticals Inc
Sienna Biopharmaceuticals Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Aclaris Therapeutics Inc
Arrien Pharmaceuticals LLC
Bristol-Myers Squibb Co
Chipscreen Biosciences Ltd
Clevexel Pharma SAS
Daewoong Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Japan Tobacco Inc
KBP BioSciences Co Ltd
LSK BioPartners Inc
Merck & Co Inc
MYOS RENS Technology Inc
Portola Pharmaceuticals Inc
Sienna Biopharmaceuticals Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
